Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models.
Li S, Hoefnagel SJM, Read M, Meijer S, van Berge Henegouwen MI, Gisbertz SS, Bonora E, Liu DSH, Phillips WA, Calpe S, Correia ACP, Sancho-Serra MDC, Mattioli S, Krishnadath KK; Members of the Esophageal Adenocarcinoma Study Group Europe (EACSGE).
Li S, et al. Among authors: gisbertz ss.
Cell Oncol (Dordr). 2022 Aug;45(4):639-658. doi: 10.1007/s13402-022-00689-2. Epub 2022 Jul 28.
Cell Oncol (Dordr). 2022.
PMID: 35902550
Free PMC article.